About
MimiVax develops SurVaxM, a peptide immunotherapeutic vaccine targeting the survivin protein to stimulate the immune system against survivin-expressing cancer cells, primarily for treating glioblastoma and other cancers through immunotherapy.
Explore MimiVax's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.